| scholarly article | Q13442814 |
| P50 | author | Elpida Tsika | Q56670281 |
| David Ramonet | Q56827676 | ||
| Alzbeta Trancikova | Q57027886 | ||
| Darren J Moore | Q87693446 | ||
| Liliane Glauser | Q115628702 | ||
| Klodjan Stafa | Q115628703 | ||
| P2093 | author name string | Juan C. Troncoso | |
| Olga Pletnikova | |||
| Sarah Sonnay | |||
| Agata Podhajska | |||
| P2860 | cites work | Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. | Q21135493 |
| Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 | ||
| Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism | Q24301367 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| Subversion of cellular autophagosomal machinery by RNA viruses | Q24522711 | ||
| Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy | Q24683089 | ||
| Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes | Q24810483 | ||
| A noncytotoxic DsRed variant for whole-cell labeling | Q27652674 | ||
| Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity | Q27934988 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| The E646D-ATP13A4 mutation associated with autism reveals a defect in calcium regulation | Q28506199 | ||
| How to interpret LC3 immunoblotting | Q29614175 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| Autophagy gone awry in neurodegenerative diseases | Q29614849 | ||
| The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses | Q29615239 | ||
| Regulation of Intracellular Manganese Homeostasis by Kufor-Rakeb Syndrome-associated ATP13A2 Protein | Q34197130 | ||
| Characterization of the P5 subfamily of P-type transport ATPases in mice | Q34350143 | ||
| Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia | Q34429799 | ||
| Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability | Q34534474 | ||
| Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome | Q34726815 | ||
| α-Synuclein impairs macroautophagy: implications for Parkinson's disease. | Q35005567 | ||
| Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein | Q35063363 | ||
| Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death | Q35175069 | ||
| Molecular pathophysiology of Parkinson's disease | Q36196507 | ||
| Genetics of Parkinson's disease and parkinsonism | Q36636210 | ||
| Functions and dysfunctions of mitochondrial dynamics | Q36967747 | ||
| Mendelian forms of Parkinson's disease | Q37376999 | ||
| Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease | Q37402225 | ||
| Regulation of mammalian autophagy in physiology and pathophysiology. | Q37801517 | ||
| Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells | Q39738033 | ||
| A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. | Q40601003 | ||
| Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. | Q40616484 | ||
| Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2 | Q41899742 | ||
| Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations | Q42947297 | ||
| ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation | Q43121326 | ||
| ATP13A2 variants in early-onset Parkinson's disease patients and controls | Q44289614 | ||
| Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies | Q46184361 | ||
| Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore | Q46241226 | ||
| PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE | Q56772080 | ||
| Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation | Q61782148 | ||
| Biochemical Fractionation of Brain Tissue for Studies of Receptor Distribution and Trafficking | Q62607676 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 8 | |
| P921 | main subject | ATPase cation transporting 13A2 | Q21115193 |
| ATPase type 13A2 | Q21499116 | ||
| autophagosome organization | Q24458610 | ||
| P304 | page(s) | 1725–1743 | |
| P577 | publication date | 2012-04-15 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity | |
| P478 | volume | 21 |
| Q38211382 | A mitocentric view of Parkinson's disease. |
| Q67230494 | A pH-correctable, DNA-based fluorescent reporter for organellar calcium |
| Q33715666 | ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies |
| Q28116203 | ATP13A2 and Alpha-synuclein: a Metal Taste in Autophagy |
| Q28119120 | ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons |
| Q50299651 | ATP13A2 transports cations from cytosol to lysosomal lumen |
| Q34774337 | ATP13A2/PARK9 Deficiency Neither Cause Lysosomal Impairment Nor Alter α-Synuclein Metabolism in SH-SY5Y Cells |
| Q28118666 | ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein |
| Q51732455 | Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. |
| Q98224600 | Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective |
| Q35018773 | CATP-6, a C. elegans ortholog of ATP13A2 PARK9, positively regulates GEM-1, an SLC16A transporter |
| Q38080980 | Cell biology and function of neuronal ceroid lipofuscinosis-related proteins |
| Q27003886 | Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders |
| Q35795120 | Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants |
| Q92686541 | Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype |
| Q34286404 | Common Pathogenic Effects of Missense Mutations in the P-Type ATPase ATP13A2 (PARK9) Associated with Early-Onset Parkinsonism |
| Q30653185 | Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration |
| Q23914777 | Correlation between the biochemical pathways altered by mutated Parkinson-related genes and chronic exposure to manganese |
| Q47169769 | Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease |
| Q52095699 | Diagnosis of CoPAN by whole exome sequencing: Waking up a sleeping tiger's eye. |
| Q92875576 | Emerging Role of Genetic Alterations Affecting Exosome Biology in Neurodegenerative Diseases |
| Q26764724 | Emerging preclinical pharmacological targets for Parkinson's disease |
| Q38684233 | Endocytic membrane trafficking and neurodegenerative disease |
| Q50176511 | Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein |
| Q36210852 | Exercise-mimetic AICAR transiently benefits brain function |
| Q39057306 | Exosomes in Parkinson's Disease |
| Q38557027 | Genes associated with Parkinson's disease: regulation of autophagy and beyond |
| Q50248457 | Genetic analysis of the ATP1B4 gene in Chinese Han patients with Parkinson's disease |
| Q22242985 | Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease |
| Q94586186 | Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis |
| Q34550197 | Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways |
| Q64073224 | Glial phagocytic clearance in Parkinson's disease |
| Q24337043 | Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity |
| Q28510024 | Impaired Glucose Tolerance in a Mouse Model of Sidt2 Deficiency |
| Q39044609 | Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism |
| Q34629875 | Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis |
| Q39377457 | Influence of iron metabolism on manganese transport and toxicity |
| Q92213047 | Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing |
| Q28588670 | LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance |
| Q47813940 | Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). |
| Q37461364 | Lysosomal impairment in Parkinson's disease |
| Q38479949 | Manganese Is Essential for Neuronal Health |
| Q36100354 | Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease |
| Q39247520 | Mechanisms of Gene-Environment Interactions in Parkinson's Disease |
| Q52332617 | Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives. |
| Q92129107 | Mitophagy in Parkinson's Disease: From Pathogenesis to Treatment |
| Q38887346 | Molecular changes in the postmortem parkinsonian brain |
| Q64109210 | Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion |
| Q34100399 | Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review |
| Q92275527 | Neurodegeneration with Brain Iron Accumulation |
| Q64230486 | Neurodegeneration with Brain Iron Accumulation Disorders: Valuable Models Aimed at Understanding the Pathogenesis of Iron Deposition |
| Q21129274 | Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms |
| Q59812935 | New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease |
| Q36381145 | On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation |
| Q90310268 | PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease |
| Q50418431 | Parkinson disease related ATP13A2 evolved early in animal evolution. |
| Q26746899 | Parkinson's Disease: The Mitochondria-Iron Link |
| Q33582743 | Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction |
| Q33991769 | Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration |
| Q38727638 | Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance |
| Q94371699 | Parkinson’s Disease |
| Q53387936 | Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression |
| Q34481921 | Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease |
| Q36800670 | Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. |
| Q64915273 | Synergistic Effect of Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease. |
| Q38434200 | The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms |
| Q39281423 | The role of Ca2+ signaling in Parkinson's disease |
| Q38765856 | Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. |
| Q28116171 | Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation |
Search more.